Commonwealth Diagnostics International (CDI) Named Among the Top Healthcare Technology Companies of 2022

CDI recognized for commitment to delivering patient-centric, cost-effective portfolio of diagnostic and technology solutions to the GI community
1 2 3
CDI's experienced lab staff
CDI's experienced lab staff
SALEM, Mass. - Aug. 18, 2022 - PRLog -- Commonwealth Diagnostics International, Inc. (CDI), an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose common sources of digestive distress and functional gastrointestinal ailments, is proud to be recognized as one of the Top 100 Healthcare Technology Companies of 2022 by The Healthcare Technology Report, a leading source of information related to the healthcare technology industry. The annual list honors healthcare technology companies based on their dedication to finding innovative ways to save lives and improve patient care in the medical space.

"The top 100 companies this year represent a range of specialties, from genomics to pharmaceuticals, lab testing, therapeutics, data analysis, and much more," stated the announcement from The Healthcare Technology Report. "They are driving the industry forward and creating an environment in which better care for all is possible."

CDI was recognized for its commitment to delivering a patient-centric, cost-effective portfolio of diagnostic solutions that result in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system.

"We have seen a tremendous shift from point-of-care to at-home diagnostics, leading to significant growth over the past several years," said Craig Strasnick, President and CEO of CDI. "With additional equipment, technology, and staff investments, we stay committed to delivering an industry-leading diagnostic experience to our provider partners and their patients."

CDI's expansive portfolio of diagnostic and technology solutions includes:
  • Non-invasive at-home breath testing kits for Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methanogen Overgrowth (IMO), and carbohydrate malabsorption disorders
  • IBSchek, a proprietary capillary collection test for Irritable Bowel Syndrome (IBS-D/M)
  • MyGi Health, a cloud-based healthcare platform that enables patients to manage and understand their GI-related symptoms.

Founded in 2015 in Salem, Massachusetts, and operating out of its CLIA-certified laboratory and as an FDA-registered, ISO 13485-certified medical device manufacturer, CDI has partnerships with leading health systems, hospitals, and private practices worldwide. To learn more, visit

For The Healthcare Technology Report's complete list of The Top 100 Healthcare Technology Companies of 2022, visit


Like PRLog?
Click to Share